Utah Retirement Systems Sage Therapeutics, Inc. Transaction History

Utah Retirement Systems

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$54.88 - $79.29 $148,176 - $214,083	-2,700 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$70.65 - $96.76 $7,065 - $9,676	100 Added 3.85%	2,700 $202,000
Q4 2020 Feb 16, 2021	BUY	$58.41 - $89.06 $151,866 - $231,556	2,600 New	2,600 $225,000
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $399,454 - $606,514	-9,712 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$26.15 - $77.24 $2,615 - $7,723	-100 Reduced 1.02%	9,712 $279,000
Q4 2019 Feb 12, 2020	BUY	$60.18 - $154.77 $18,054 - $46,431	300 Added 3.15%	9,812 $709,000
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $14,029 - $18,996	100 Added 1.06%	9,512 $1.34 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $29,202 - $33,871	185 Added 2.0%	9,412 $1.72 Million
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $73,875 - $135,338	827 Added 9.85%	9,227 $1.47 Million
Q2 2018 Aug 10, 2018	BUY	$140.36 - $175.76 $1.18 Million - $1.48 Million	8,400 New	8,400 $1.31 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $330M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Utah Retirement Systems, based on Form 13F filings with the SEC.

Stay updated on Utah Retirement Systems with notifications on news.